>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
Measured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR (Catalog # 2530‑CD)
is coated at 2.5 μg/mL (100 μL/well), the concentration of Recombinant
Human TIGIT Fc Chimera that produces 50% optimal binding response is
typically 8-48 ng/mL.
Human embryonic kidney cell, HEK293-derived human TIGIT protein
When Recombinant Human CD155/PVR (Catalog # 2530‑CD) iscoated at 2.5 µg/mL (100 μL/well), Recombinant Human TIGIT Fc Chimera(Catalog # 9464‑TG) binds with a typical ED50 of 8-48 ng/mL.
(T cell Immunoreceptor with Ig and ITIM domains), also called Vstm3 (V-set and
transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9)
and WUCAM (Washington University cell adhesion molecule) is a 30-34 kDa type I
transmembrane protein that is a member of the CD28 family within the Ig
superfamily of proteins (1-4). Human TIGIT cDNA encodes 244 amino acids (aa)
including a 21 aa signal sequence, a 120 aa extracellular region with a V-type
Ig-like domain and two potential N-glycosylation site, a 21 aa transmembrane
sequence, and an 82 aa cytoplasmic domain with an ITIM motif (5). A 170 aa
variant diverges after aa 166 (5). Within the ECD, human TIGIT shares only
68-75% aa sequence identity with mouse, porcine, canine, equine and bovine
TIGIT (1, 2). Binding of TIGIT by DC induces IL-10 release and inhibits IL-12
production (2). Ligation of TIGIT on T cells down‑regulates TCR-mediated activation and subsequent
proliferation, while NK cell TIGIT ligation blocks NK cell cytotoxicity (6-8).
Through CD155 and Nectin-2, which also interact with DNAM-1/CD226 and
CD96/Tactile, TIGIT is part of an interacting network of Ig superfamily members
that may augment or oppose each other (3, 4, 6, 7). In particular, TIGIT binding
to CD155 can antagonize the effects of DNAM-1 (6, 7). Soluble TIGIT is able to
compete with DNAM-1 for CD155 binding and attenuates T cell responses, while
mice lacking TIGIT show increased T cell responses and susceptibility to
autoimmune challenges (2, 3, 8).
Boles, K.S. et al. (2009) Eur. J. Immunol. 39:695.
Yu, X. et al. (2009) Nat. Immunol. 10:48.
Levin, S.D. et al. (2011) Eur. J. Immunol. 41:902
Xu, Z. et al. (2010) Cell. Mol. Immunol. 7:11.
SwissProt Accession # Q495A1.
Seth, S. et al. (2009) Eur. J. Immunol. 39:3160.
Stanietsky, N. et al. (2009) Proc. Natl. Acad. Sci. USA 106:17858.
Have you used Recombinant Human TIGIT (T103) Fc Chimera Protein, CF?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.